MeiraGTx Holdings plc (MGTX)
MeiraGTx Holdings plc operates in the Biotechnology industry of the Healthcare sector, headquartered in New York City, NY, US. The stock last traded at $13.25, up 1.53% on the session, giving a market capitalisation of $1.23B. On trailing twelve-month figures it carries a trailing P/E of 17.43, a net margin of 19.9%. Its beta of 1.27 implies it has historically moved more than the broad market.
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
MeiraGTx Holdings plc is most often compared with the following Healthcare names: